Skip to content

Skeletal Muscle and Platelet Mitochondrial Dysfunction During Sepsis

Skeletal Muscle and Platelet Mitochondrial Dysfunction During Sepsis

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00541827
Enrollment
50
Registered
2007-10-10
Start date
2007-10-31
Completion date
2012-08-31
Last updated
2013-09-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Septic Shock, Severe Sepsis

Keywords

Sepsis. Shock, septic. Mitochondria.

Brief summary

The primary aim of the study is to demonstrate that mitochondrial dysfunction occurs in both skeletal muscle and circulating platelets of severely septic and septic shock ICU-admitted patients. Secondary aims are to clarify the pathogenesis and the clinical relevance of mitochondrial damage during sepsis.

Detailed description

The primary aim of the study is to demonstrate that mitochondrial dysfunction occurs in both skeletal muscle and circulating platelets of severely septic and septic shock ICU-admitted patients, as compared to otherwise healthy surgical ones. In order to better clarify the pathogenesis of mitochondrial dysfunction during sepsis, cardiogenic shock patients (suffering from systemic hypoperfusion) will act as additional controls. Markers of oxidative stress will be measured in tissue samples from septic patients. The clinical relevance of mitochondrial dysfunction during sepsis will be assessed in terms of both skeletal muscle and platelet function.

Interventions

None listed

Sponsors

European Society of Intensive Care Medicine
CollaboratorOTHER
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Consecutive ICU-admitted severely septic or septic shock patients.

Exclusion criteria

* Severe thrombocytopenia. * Severe coagulopathy. * Pre-existing mitochondrial disease

Design outcomes

Primary

MeasureTime frame
Mitochondrial respiratory chain enzyme activityOn day one and seven from admission to ICU

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 18, 2026